Patricia Diaz-Galvan
Overview
Explore the profile of Patricia Diaz-Galvan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferreira D, Przybelski S, Lesnick T, Diaz-Galvan P, Schwarz C, Murray M, et al.
JAMA Neurol
. 2025 Jan;
82(3):285-294.
PMID: 39804619
Importance: Although 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a well-established cross-sectional biomarker of brain metabolism in dementia with Lewy bodies (DLB), the longitudinal change in FDG-PET has not been characterized....
2.
Patients with dementia with Lewy bodies display a signature alteration of their cognitive connectome
Yanez-Perez R, Garcia-Cabello E, Habich A, Cedres N, Diaz-Galvan P, Abdelnour C, et al.
Sci Rep
. 2025 Jan;
15(1):940.
PMID: 39762366
Cognition plays a central role in the diagnosis and characterization of dementia with Lewy bodies (DLB). However, the complex associations among cognitive deficits in different domains in DLB are largely...
3.
Diaz-Galvan P, Przybelski S, Algeciras-Schimnich A, Figdore D, Lesnick T, Schwarz C, et al.
Alzheimers Dement
. 2024 Feb;
20(4):2485-2496.
PMID: 38329197
Introduction: Patients with dementia with Lewy bodies (DLB) may have Alzheimers disease (AD) pathology that can be detected by plasma biomarkers. Our objective was to evaluate plasma biomarkers of AD...
4.
Rodriguez-Hernandez M, Alemany I, Olofsson J, Diaz-Galvan P, Nemy M, Westman E, et al.
Neurosci Biobehav Rev
. 2024 Jan;
157:105534.
PMID: 38220033
Background: Subjective cognitive decline (SCD) is a risk factor for future cognitive impairment and dementia. It is uncertain whether the neurodegeneration of the cholinergic system is already present in SCD...
5.
Oltra J, Habich A, Schwarz C, Nedelska Z, Przybelski S, Inguanzo A, et al.
Alzheimers Dement
. 2023 Dec;
20(3):1815-1826.
PMID: 38131463
Introduction: Sex influences neurodegeneration, but it has been poorly investigated in dementia with Lewy bodies (DLB). We investigated sex differences in brain atrophy in DLB using magnetic resonance imaging (MRI)....
6.
Diaz-Galvan P, Lorenzon G, Mohanty R, Martensson G, Cavedo E, Lista S, et al.
Alzheimers Res Ther
. 2023 Oct;
15(1):177.
PMID: 37838742
No abstract available.
7.
Zapater-Fajari M, Diaz-Galvan P, Cedres N, Rydberg Sterner T, Ryden L, Sacuiu S, et al.
J Gerontol A Biol Sci Med Sci
. 2023 Sep;
79(2).
PMID: 37708068
Background: Subjective cognitive decline (SCD) has gained recent interest as a potential harbinger of neurodegenerative diseases such as Alzheimer's disease (AD) and cerebrovascular disease (CVD). In addition, SCD can be...
8.
Diaz-Galvan P, Lorenzon G, Mohanty R, Martensson G, Cavedo E, Lista S, et al.
Alzheimers Res Ther
. 2023 Jun;
15(1):117.
PMID: 37353809
Background: Donepezil is an approved therapy for the treatment of Alzheimer's disease (AD). Results across clinical trials have been inconsistent, which may be explained by design-methodological issues, the pathophysiological heterogeneity...
9.
Diaz-Galvan P, Przybelski S, Lesnick T, Schwarz C, Senjem M, Gunter J, et al.
Neurology
. 2023 May;
101(2):e178-e188.
PMID: 37202168
Background And Objectives: β-Amyloid (Aβ) plaques can co-occur with Lewy-related pathology in patients with dementia with Lewy bodies (DLB), but Aβ load at prodromal stages of DLB still needs to...
10.
Diaz-Galvan P, Miyagawa T, Przybelski S, Lesnick T, Senjem M, Jack Jr C, et al.
Brain Commun
. 2023 Feb;
5(1):fcad021.
PMID: 36844148
Alterations of cerebral glucose metabolism can be detected in patients with isolated rapid eye movement sleep behaviour disorder, a prodromal feature of neurodegenerative diseases with α-synuclein pathology. However, metabolic characteristics...